Your browser doesn't support javascript.
loading
Rapid response flow cytometric assay for the detection of antibody responses to SARS-CoV-2
Dennis Lapuente; Clara Maier; Pascal Irrgang; Julian Huebner; Sophia Antonia Peter; Markus Hoffmann; Armin Ensser; Katharina Ziegler; Thomas H. Winkler; Thorsten Birkholz; Andreas E. Kremer; Philipp Steininger; Klaus Korn; Frank Neipel; Klaus Ueberla; Matthias Tenbusch.
Affiliation
  • Dennis Lapuente; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
  • Clara Maier; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
  • Pascal Irrgang; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
  • Julian Huebner; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
  • Sophia Antonia Peter; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
  • Markus Hoffmann; Leibniz Institute for Primate Research, Goettingen, Germany
  • Armin Ensser; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
  • Katharina Ziegler; Paracelsus Medical University, Nuremberg, Germany
  • Thomas H. Winkler; Department of Biology, Division of Genetics, Nikolaus-Fiebiger-Center for Molecular Medicine, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germa
  • Thorsten Birkholz; Department of Anaesthesiology, University Hospital Erlangen, Erlangen, Germany
  • Andreas E. Kremer; Department of Medicine 1, Gastroenterology, Pneumology and Endocrinology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlan
  • Philipp Steininger; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
  • Klaus Korn; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
  • Frank Neipel; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
  • Klaus Ueberla; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
  • Matthias Tenbusch; Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
Preprint in En | PREPRINT-MEDRXIV | ID: ppmedrxiv-20091447
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
SARS-CoV-2 has emerged as a previously unknown zoonotic coronavirus that spread worldwide causing a serious pandemic. While reliable nucleic acid-based diagnostic assays were rapidly available, there exists only a limited number of validated serological assays. Here, we evaluated a novel flow cytometric approach based on antigen-expressing HEK 293T cells to assess spike-specific IgG and IgM antibody responses. Analyses of 201 pre-COVID-19 sera proved a high assay specificity in comparison to commercially available CLIA and ELISA systems, while also revealing the highest sensitivity in specimens from PCR-confirmed SARS-CoV-2 infected patients. Additionally, a soluble Angiotensin-Converting-Enzyme 2 (ACE-2) variant was established as external standard to quantify spike-specific antibody responses on different assay platforms. In conclusion, our newly established flow cytometric assay allows sensitive and quantitative detection of SARS-CoV-2-specific antibodies, which can be easily adopted in different laboratories and does not rely on external supply of assay kits.
License
cc_no
Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Diagnostic_studies / Experimental_studies / Prognostic_studies Language: En Year: 2020 Document type: Preprint
Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Diagnostic_studies / Experimental_studies / Prognostic_studies Language: En Year: 2020 Document type: Preprint